ManpowerGroup Inc. (MAN): what the price assumes

boothcheck covers ManpowerGroup Inc. (MAN) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/MAN

Headline

FieldValue
TickerMAN
CompanyManpowerGroup Inc.
Current price$56.50/sh
CompositionStaffing and Interim 88% / Outcome-Based Solutions and Consulting 7% / Permanent Recruitment 2% / Other 3%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)1.7%
Operating margin (mid-cycle)2.9%
Margin compression (value-band)-1.2pp
Trailing margin (depressed year)0.8%
Multiple paid8x mid-cycle operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 4.1% sits below it).

How unusual the bet is: within-range

ReferenceValue
vs own history+0.30σ
cohort percentile (of 222 peers)3
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and relative-multiple value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.43x3expensive
Earnings0.77x1justifies
Relative0.06x3justifies
Growth1.35x1expensive

Families that justify the price: Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.4%); the inversion above states its own rate.

Per-Model Detail (n=8)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$975.440.06xyesP/S fallback (negative EPS): Sector P/S 2.5x × TTM revenue — excluded from consensus
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$43.841.29xyesReference only (book value floor): BV/sh $43.84, ROE negative
Two-Stage Excess ReturnAsset$39.461.43xyesReference only (book value with convergence): BV/sh $43.84, ROE converges to ke
Discounted Future Market CapGrowth$41.951.35xyesRev $18.4B, growth 5% (input: historical growth; tapered), Terminal P/S: 0.1x / 0.1x / 0.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$73.820.77xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.41B × (1−21%) / WACC 8.4% → EPV (no growth)
Residual IncomeAssetno
Graham NumberAssetno
EV/EBITDA RelativeRelative$37.481.51xyesEBITDA $0.17B × sector EV/EBITDA 12.0x
FCF YieldEarningsno
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarningsno
ROIC-Justified P/BAsset$4.9711.37xyesBV $43.84 × (ROIC 1.0% / WACC 8.4%)
P/Sales SectorRelative$975.440.06xyesRevenue $18.38B × sector P/S 2.5x
PEG Fair ValueRelativeno
Earnings YieldEarningsno
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net debt$1.5b
Net debt / NOPAT (after-tax)3.66x
Net debt / operating income (pre-tax)2.89x
Share count CAGR (buyback)-3.5%
Burning cashyes

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 2.9%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Trailing earnings tell you almost nothing useful here. ManpowerGroup is at the bottom of the staffing cycle, with an operating margin of just 0.8% against a 2.9% mid-cycle level, so the standard P/E lens makes a normal business look broken.

The price is supported by asset value, normalized earnings power, and peer multiples. At $33.62 it trades below the value those frames imply, and the company is buying back stock at roughly 3.5% of the share count a year while paying a 4.9% dividend.

The risk is that trough becomes the trend. European bench utilization and permanent recruitment are weak, free cash flow is guided negative in the first half of 2026, and net debt sits at nearly four times trough operating income.

Bull Case

What the standard valuation lens misses about ManpowerGroup is the cycle. Staffing is one of the most cyclical businesses in the market, and the company is sitting near a trough: the trailing operating margin is just 0.8%, against a mid-cycle figure closer to 2.9%. Run a P/E on trough earnings and you get a frightening number that says nothing about normal earnings power, because the denominator is temporarily crushed. Q1 2026 made the point starkly, with net earnings of only $2.5 million and diluted EPS of $0.05, almost entirely the result of an 83.8% effective tax rate driven by earnings mix, restructuring, and French taxes, not a collapse in the business. The numbers on the page understate the business; the gap between reported and normalized is the opportunity.

When you value the normalized business, the price looks like a value setup. Against the $33.62 (June 27, 2026) quote, the asset-based, earnings-power, and relative-multiple families all support the price, and the blended figure lands near $43.84. Revenue is actually growing: Q1 2026 revenue rose 10.3% to $4.51 billion, 2.9% in constant currency, with broad-based gains across Southern Europe, Northern Europe, and APME. The 10-K documents the geographic engine, noting revenue increases in Southern Europe and the contribution of the Manpower staffing brand across the portfolio (FY2025 10-K, accession 0001193125-26-064113). The top line is not the problem; margin is, and margin is cyclical.

Management is using the downturn to reset the cost base and reward holders. The company has launched a global transformation program targeting $200 million of permanent cost savings by 2028, leveraging automation and AI across operations that already touch nearly 90% of the business, which lifts the mid-cycle margin if it executes. Meanwhile it returns cash aggressively: a semi-annual dividend of $0.72 per share for a roughly 4.9% yield, in the top quartile of US payers, and a share count shrinking about 3.5% a year. A market-leading global staffer, ranked number one on Forbes' 2026 list of US temporary staffing firms, trading below normalized value while it cuts costs and buys back stock into a cyclical trough, is exactly the kind of name where the reported P/E is the worst possible guide.

Bear Case

The valuation methods do not actually agree, and the disagreement is the bear's opening. Only three methods apply here, and the entire bull case rests on normalizing the margin back to a mid-cycle 2.9% from today's 0.8%. The asset-based and earnings-power methods that support the price are leaning on that normalization; the forward-growth method is the one that has to assume the recovery happens. When a thesis depends on a single assumption, that the cycle turns and margin reverts, the conservative reading is to ask what happens if it does not. The reported numbers are not just optically bad, they reflect real weakness: Q1 2026 gross margin fell to 16.0% from 17.1% on "lower bench utilization in Europe and mix shifts impacting staffing margin," with weaker permanent recruitment and managed-service activity.

The operating cash position is the part holders would rather not dwell on. Management guided free cash flow to be negative in the first half of 2026, and the business already posted a Q1 cash outflow of $135 million. The 10-K explains the structural reason this is dangerous in a downturn that lingers: as demand shifts, working capital swings because the company pays associates weekly or monthly "while the related accounts receivable is outstanding for much longer, which may result in a decline in operating cash flows" (FY2025 10-K, accession 0001193125-26-064113). Negative free cash flow plus net debt of roughly $1.53 billion, at nearly four times trough operating income, is a balance-sheet profile that gets uncomfortable if the European softness persists into 2027.

The demand backdrop is not clearly inflecting up. ManpowerGroup's own Net Employment Outlook for Q3 2026 was 35%, down seven points quarter over quarter, and the European staffing markets that drove the revenue line are exactly where the margin pressure sits. The 10-K's risk factors name the structural exposures plainly, including competition in labor markets and "political unrest, natural disasters, health crises, infrastructure disruptions and other risks beyond our control" (FY2025 10-K, accession 0001193125-26-064113). The $200 million cost-savings program is a 2028 promise, not a 2026 result, and it relies on AI and automation displacing the company's own labor-intensive processes. If the cycle stays soft, the buyer is holding a leveraged, cash-burning staffer whose value is supported only on the assumption that normal returns soon.

Valuation

The valuation hinges entirely on reading through the cycle. ManpowerGroup is priced on operating income, and the current trailing operating margin of 0.8% is well below the 2.9% mid-cycle figure the model uses to normalize. Against the $33.62 price, the asset-based, earnings-power, and relative-multiple families all support the price, and the blended X-ray figure across the three applicable methods lands near $43.84, above the quote. The priced-in characterization is within range and explicitly value and asset-supported rather than a growth bet, which fits a cyclical at a trough: the price is not demanding growth, it is assuming reversion to a normal margin.

The leverage is the caveat that the thin trough earnings make sharper. Net debt of about $1.53 billion against trailing operating income of roughly $150 million is nearly four times, a ratio that looks alarming only because the denominator is at a cyclical low. On mid-cycle earnings the leverage is far more manageable, which is the same normalization the equity value depends on. Interest expense is not separately reported in the filings, so coverage cannot be cleanly computed, a wrinkle worth flagging for a leveraged name guiding to negative near-term free cash flow.

The asset support gives a floor, the earnings-power support assumes a mid-cycle margin the company is not currently earning, and the relative-multiple support compares it to peers also living through the same downturn. The 10-K's segment detail confirms the revenue base is intact across Europe (FY2025 10-K, accession 0001193125-26-064113); the question the price answers is whether margin reverts. If the $200 million cost program and a cyclical recovery lift the margin toward 2.9%, the price is cheap; if the trough persists, the leverage and negative cash flow turn the value support into a value trap.

Catalysts

Q1 2026 results (reported April 2026) showed growth on the top line and pain below it. Revenue rose 10.3% to $4.51 billion, 2.9% in constant currency, led by Southern Europe, Northern Europe, and APME, but gross margin fell to 16.0% from 17.1% on lower European bench utilization and mix shifts, and net earnings were just $2.5 million, EPS $0.05, due largely to an 83.8% effective tax rate. Management guided free cash flow to be negative in the first half of 2026 after a $135 million Q1 outflow, so the cadence of margin and cash flow through the year is the near-term catalyst that matters most.

The transformation program is the structural catalyst. ManpowerGroup is targeting $200 million of permanent cost savings by 2028 through automation and AI across operations that already serve nearly 90% of the business, plus a new AI-powered interviewing partnership. Evidence that these savings are landing, and lifting the mid-cycle margin, would validate the normalization the valuation assumes. The company's own Employment Outlook Survey is a useful leading indicator: the Q3 2026 Net Employment Outlook of 35% was down seven points sequentially, a sign demand has not yet inflected.

The income and sentiment picture provides interim support. The semi-annual dividend of $0.72 per share, a roughly 4.9% yield in the top quartile of US payers, and ongoing buybacks reward patience while the cycle plays out. Twelve covering analysts rate the stock Buy on average with a price target near $35.94, modestly above the current price. The catalysts that would re-rate it are a turn in European staffing demand, visible progress on the cost program, and a return to positive free cash flow in the back half of 2026.

Peer Cohorts (Per Segment, With Filing Citations)

Southern Europe / Northern Europe / APME (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive MAN report on boothcheck